Emerging Growth Research to manage investor relations programs for Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced it has retained Emerging Growth Research, LLP to manage its public relations and investor relations programs. Emerging Growth Research specializes in small market capitalization companies in the technology and biotechnology sectors.

“We are very excited to be working with Joe Noel and Emerging Growth Research, LLP. The firm's track record in assisting smaller sized emerging companies in getting its story out to investors, vendors, and the public is impressive,” commented Clayton Hardman, CEO of Biomagnetics Diagnostic, Corp. “We are preparing to enter some very exciting areas, especially relating to malaria and bovine tuberculosis testing. We plan on launching some of the most innovative technologies within this market space and we believe Emerging Growth Research will be instrumental in our investor, capital formation, and vendor-related efforts. We look forward to working with them over the coming year.”

According to the World Health Organization some 3.2 billion people, or about half the world's population, is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. In the case of malaria, early detection substantially improves treatability and survivability. TB (tuberculosis) is the second leading cause of death from infectious disease worldwide. Bovine TB is a growing problem throughout the world with an estimated 1.3 billion cattle at risk. In the United States where the cattle industry is valued at $60 billion annually, the use of existing diagnostic tests currently add $5.00 to $15.00 on average per head to the cattle industry's costs. Field deployable Integrated Optical Biosensor Systems (IBOS), such as those Biomagnetics Diagnostics plans to introduce to the market, hold the promise to significantly speed diagnostic testing in the field which would meaningfully lower costs.

Source: Biomagnetics Diagnostics Corp.